ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen Says Recent Sensipar Study Failed to Meet Primary Endpoint

By Mia Lamar Amgen Inc. (AMGN) said Friday that a study evaluating its Sensipar drug for effectiveness in reducing the risk of mortality and cardiovascular events in patients suffering from chronic kidney disease failed to meet its primary endpoint. Sensipar--which is marketed as Mimpara in Europe--was first approved in 2004 to treat thyroid problems in patients with kidney disease and cancer. The company recorded $808 million in global sales of the drug last year. Amgen said Friday it undertook the Phase 3 trial of Sensipar to discover whether the drug could positively impact the high rates of mortality and incidences like heart failure experienced by patients with chronic kidney disease that are receiving dialysis. Results, however, were not statistically significant, Amgen said. The company noted analyses from the study are ongoing and will be submitted for presentation at a major medical meeting later this year. Amgen, the biggest stand-alone biotechnology company, has been pursuing deals to bolster its research-and-development pipeline as sales growth slows for older drugs. Shares were recently off 26 cents to $68.84. Write to Mia Lamar at mia.lamar@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
06/22/201618:00:00Amgen Sponsors QB3@953 Incubator For Life Science Startups
06/20/201608:25:00Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa...
06/17/201616:00:00Amgen Appoints Esteban Santos Executive Vice President, Operations
06/15/201616:58:28Annual Report of Employee Stock Plans (11-k)
06/15/201616:51:42Annual Report of Employee Stock Plans (11-k)
06/14/201616:55:30Current Report Filing (8-k)
06/13/201616:00:00Amgen Announces FDA Advisory Committee Meeting To Review ABP...
06/10/201616:00:00New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib...
06/10/201609:17:28Current Report Filing (8-k)
06/10/201609:00:00Amgen Announces Expiration And Final Results Of Senior Notes...
06/10/201602:30:00BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients...
06/09/201616:18:40Statement of Changes in Beneficial Ownership (4)
06/08/201616:30:00Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients...
06/07/201609:00:00New National Survey Sheds Light On How To Better Engage Students...
06/06/201616:00:00New Phase 3 Secondary Analysis Shows Progression-Free Survival...
06/06/201612:20:00Gilead's New CEO Faces Pressures on Hepatitis C Pills
06/03/201616:15:00Amgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An...
06/03/201616:00:00Amgen To Present At The Goldman Sachs 37th Annual Global Healthcare...
06/01/201602:30:00Bayer Collaborates with U.S. National Surgical Adjuvant Breast...
05/31/201616:32:17Specialized Disclosure Report (sd)

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad